Eledon Pharmaceuticals (NASDAQ:ELDN - Get Free Report) is expected to be posting its Q4 2024 quarterly earnings results before the market opens on Thursday, March 20th. Analysts expect Eledon Pharmaceuticals to post earnings of ($0.32) per share for the quarter.
Eledon Pharmaceuticals (NASDAQ:ELDN - Get Free Report) last posted its quarterly earnings results on Thursday, March 20th. The company reported ($0.64) EPS for the quarter, missing the consensus estimate of ($0.32) by ($0.32). During the same quarter in the prior year, the firm posted ($1.00) earnings per share. On average, analysts expect Eledon Pharmaceuticals to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Eledon Pharmaceuticals Price Performance
NASDAQ ELDN traded up $0.07 during mid-day trading on Friday, hitting $3.51. The company's stock had a trading volume of 310,372 shares, compared to its average volume of 273,821. Eledon Pharmaceuticals has a 52-week low of $1.52 and a 52-week high of $5.54. The firm has a market capitalization of $209.68 million, a P/E ratio of -1.75 and a beta of 0.80. The stock's fifty day simple moving average is $4.17 and its two-hundred day simple moving average is $3.86.
Analyst Ratings Changes
Separately, Guggenheim started coverage on Eledon Pharmaceuticals in a research note on Tuesday, January 28th. They set a "buy" rating and a $9.00 target price for the company.
Read Our Latest Analysis on Eledon Pharmaceuticals
About Eledon Pharmaceuticals
(
Get Free Report)
Eledon Pharmaceuticals, Inc operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS).
Featured Articles
Before you consider Eledon Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eledon Pharmaceuticals wasn't on the list.
While Eledon Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
